Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection.
about
Injection Drug Use Quality of Life scale (IDUQOL): a validation study.Hepatitis C virus as a systemic disease: reaching beyond the liverCost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisonsSomatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort studyHealth-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment.Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases.The ongoing impacts of hepatitis c--a systematic narrative review of the literatureClinical utility of pharmacogenomics in the management of hepatitis C.Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.Clinical correlates of health-related quality of life among opioid-dependent patientsEffect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection.Injection Drug User Quality of Life Scale (IDUQOL): findings from a content validation studyAn Aggravated Trajectory of Depression and Anxiety Co-morbid with Hepatitis C: A Within-groups Study of 61 Australian Outpatients.The effect of hepatitis C virus infection on health-related quality of life in prisoners.Establishing the Melbourne Injecting Drug User Cohort Study (MIX): rationale, methods, and baseline and twelve-month follow-up resultsHealth-related quality of life in HIV-infected patients: the role of substance use.Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C.Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review.Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.Psychiatric symptoms, quality of life, and HIV status among people using opioids in Saint Petersburg, Russia.Is there room for resilience? A scoping review and critique of substance use literature and its utilization of the concept of resilience.Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin.Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C.Health-related quality of life in patients with different stages of liver disease induced by hepatitis C.Impact of chronic viral hepatitis on health-related quality of life in HIV: results from a nationally representative sample.Impaired health-related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels.An examination of the quality of life among rural and outer metropolitan injecting drug users in NSW, Australia
P2860
Q24811967-2DD2FB4A-A43D-4107-8C97-7836ABCA35CDQ26776387-5A5B6A16-BF0D-463C-9114-9F4202B08CF9Q28681550-EE72D086-7CDD-4088-A1CF-3A7D0A307C54Q33317649-35CDAC71-B348-4BE1-80E5-CD880D5A568AQ33953930-87443413-AA93-45D1-89CF-AE823BFE848DQ34012572-C7F47E95-2FF5-45E8-BF5F-FD381F699E06Q34383139-42172B81-C9E9-4E7B-994D-29E40161F5A8Q34464613-491B016B-149B-410D-9F40-D60666E1F9B2Q34795051-381101EC-4652-4C82-A29C-2B810436F306Q35226390-D38A0C16-5E9A-4E37-93F1-75F7EF63F40DQ35903305-F2D6E71A-D6A0-426F-8F94-FE0089E00CE9Q36015234-33091BBD-8A34-481E-9264-54FA98AC8898Q36364055-7F4A81C5-82D3-4D27-9900-494DD929D857Q36856011-B7E35F9E-49B1-4E26-8A43-249A4518C70FQ36952990-9372A7D0-E5B8-4F11-9011-80EADA3CD7F3Q37001459-E2BE023B-2CD3-45E1-A9A5-14FE7FEA02AAQ37327979-356E202C-D1FE-4387-870E-890D1AAD6D1FQ37536874-3F1BFBC7-5152-40CF-99A4-72D7951695B4Q37645900-23249E20-7A52-4F67-914B-9D47420B4544Q38050834-2DE894FD-4673-4655-BBE4-54C33B5B1D68Q40355130-25A63317-B922-4424-9553-793C67D68BC7Q41718636-65C5C2E5-D7D0-4579-845A-941467ACA825Q42382462-2ECA04D1-AEEE-4EC0-A1CF-C7F63BD4FD10Q44437005-D53836DC-8E55-49E1-8DC0-B11B3EB3B435Q51869405-0A7D8E0F-9832-475E-AA6C-7755BA68BC21Q51926482-26860F6A-B29B-446B-9F78-7D4C4B63A04DQ53217744-399CACF8-FFE2-4816-9AF3-B855226716F3Q58089207-411C9F66-5A49-4C7B-9125-07687A46D4CD
P2860
Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Health-related quality of life ...... c hepatitis C virus infection.
@en
Health-related quality of life ...... c hepatitis C virus infection.
@nl
type
label
Health-related quality of life ...... c hepatitis C virus infection.
@en
Health-related quality of life ...... c hepatitis C virus infection.
@nl
prefLabel
Health-related quality of life ...... c hepatitis C virus infection.
@en
Health-related quality of life ...... c hepatitis C virus infection.
@nl
P2093
P356
P1433
P1476
Health-related quality of life ...... c hepatitis C virus infection.
@en
P2093
Atle Egeland
Kjell Skaug
Kostas Vilimas
Olav Dalgard
Tore Steen
P356
10.1002/HEP.20014
P407
P577
2004-01-01T00:00:00Z